Business
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed
About this update from Medicus Pharma Ltd.
[{"type":"image","alt":"Medicus Pharma Ltd","displaySize":"","headline":null,"caption":"Medicus Pharma Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nCO_2.f05f6STHaWB5vZCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1","width":300,"height":105}},"lazy":false},{"type":"text","content":"The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026","length":189,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada.","length":596,"tagName":"p"},{"type":"text","content":"The Company’s accepted abstract: “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 studies in Healthy Female Volunteers” contains results from two randomized, placebo-controlled Phase I clinical studies involving 48 healthy premenopausal women, designed to evaluate how Teverelix is absorbed, how it suppresses reproductive hormones, its effects on bone turnover markers, and its overall safety following single subcutaneous injections.","length":519,"tagName":"p"},{"type":"text","content":"Phase 1 Results Demonstrate Rapid, Reversible Hormone Suppression with Stable Bone Markers","length":90,"tagName":"p"},{"type":"text","content":"Across both studies, 48 healthy premenopausal women received single subcutaneous doses of Teverelix (30 mg, 45 mg, or 60 mg) or placebo and were followed for approximately one month.","length":182,"tagName":"p"},{"type":"text...